Drugs /

rivoceranib

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
apatinib free base, apatinib, rivoceranib mesylate, and apatinib mesylate
Trade Name(s):
Aitan and Atan
NCI Definition [1]:
An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Upon administration, rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.

Clinical Trials

View Clinical Trials for rivoceranib

Rivoceranib has been investigated in 20 clinical trials, of which 18 are open and 2 are closed. Of the trials investigating rivoceranib, 3 are phase 1 (2 open), 5 are phase 1/phase 2 (5 open), 8 are phase 2 (7 open), and 4 are phase 3 (4 open).

EGFR Exon 19 Deletion, EGFR L858R, and EGFR A763_Y764insFQEA are the most frequent biomarker inclusion criteria for rivoceranib clinical trials.

Non-small cell lung carcinoma, breast carcinoma, and gastric adenocarcinoma are the most common diseases being investigated in rivoceranib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Rivoceranib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Rivoceranib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating rivoceranib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Aitan, 3-pyridinecarboxamide, n-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-, methanesulfonate (1:1), ATAN, apatinib mesylate, rivoceranib mesylate, -pyridinecarboxamide, n-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-, apatinib free base, yn968d1, apatinib, yn-968d1
Drug Categories [2]:
Tyrosine kinase inhibitors
Drug Target(s) [2]:
KDR, KIT, PDGFRA, RET, SRC
NCIT ID [1]:
C152237

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.